209 related articles for article (PubMed ID: 29121363)
21. SUBFOVEAL CHOROIDAL THICKNESS IN PAPILLITIS TYPE OF VOGT-KOYANAGI-HARADA DISEASE AND IDIOPATHIC OPTIC NEURITIS.
Maruko I; Iida T; Sugano Y; Go S; Sekiryu T
Retina; 2016 May; 36(5):992-9. PubMed ID: 26509220
[TBL] [Abstract][Full Text] [Related]
22. Vogt-koyanagi-harada disease with onset in elderly patients aged 68 to 89 years.
Yamamoto Y; Fukushima A; Nishino K; Koura Y; Komatsu T; Ueno H
Jpn J Ophthalmol; 2007; 51(1):60-3. PubMed ID: 17295144
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.
Umran RMR; Shukur ZYH
Mod Rheumatol; 2018 Jan; 28(1):197-199. PubMed ID: 26154298
[TBL] [Abstract][Full Text] [Related]
24. Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.
Bellanca RF; Pinna A; Catania G; Belcastro E; Angi M; D'Amico Ricci G
Ocul Immunol Inflamm; 2023 Feb; 31(2):402-406. PubMed ID: 35113757
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic regimen in Vogt-Koyanagi-Harada syndrome].
Yang P; Wang H; Zhou H; Zhong H; Li F; Huang X; Zhong H; Fu T
Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):196-9. PubMed ID: 12133384
[TBL] [Abstract][Full Text] [Related]
26. Vogt-Koyanagi-Harada syndrome--a case report.
Yusof Z; Pratap RC; Nor M; Reddy TN
Med J Malaysia; 1990 Mar; 45(1):70-3. PubMed ID: 2152072
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
28. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
29. Vogt-Koyanagi-Harada syndrome.
Akram S; Khabir K
J Coll Physicians Surg Pak; 2014 Sep; 24(9):692-4. PubMed ID: 25233979
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
31. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
[TBL] [Abstract][Full Text] [Related]
32. Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature.
Berker N; Ozdamar Y; Soykan E; Ozdal P; Ozkan SS
Ocul Immunol Inflamm; 2007; 15(4):351-7. PubMed ID: 17763135
[TBL] [Abstract][Full Text] [Related]
33. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
Rapisuwon S; Izar B; Batenchuk C; Avila A; Mei S; Sorger P; Parks JM; Cooper SJ; Wagner D; Zeck JC; Charabaty AJ; Atkins MB
J Immunother Cancer; 2019 Mar; 7(1):61. PubMed ID: 30832716
[TBL] [Abstract][Full Text] [Related]
34. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
Agarwal M; Ganesh SK; Biswas J
Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
[TBL] [Abstract][Full Text] [Related]
35. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease.
Errera MH; Fardeau C; Cohen D; Navarro A; Gaudric A; Bodaghi B; Westcott M; LeHoang P
Acta Ophthalmol; 2011 Jun; 89(4):e357-66. PubMed ID: 21251241
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study of Vogt-Koyanagi-Harada syndrome (author's transl)].
Kawata K
Fukuoka Igaku Zasshi; 1978 Nov; 69(11):473-85. PubMed ID: 738693
[No Abstract] [Full Text] [Related]
37. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
38. A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy.
Minami K; Egawa M; Kajita K; Murao F; Mitamura Y
Case Rep Ophthalmol; 2021; 12(3):952-960. PubMed ID: 35082654
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
40. Case of probable Vogt-Koyanagi-Harada syndrome: A rare presentation.
Mehta KN; Daigavane S
Indian J Ophthalmol; 2022 Jul; 70(7):2684-2686. PubMed ID: 35791205
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
